← SynDRA
CAPIVASERTIB
SynDRA canonical compound SYN0036679 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | AKT1 | AKT2 | AKT3 |
|---|
| Mechanism of action | AKT inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AKT2 INHIBITOR
- Serine/threonine-protein kinase AKT inhibitor
- AKT3 INHIBITOR
- AKT1 INHIBITOR
- AKT3 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PRKCQ
- PKN1
- PRKAG2
- GRK2
- FGFR1
- ROCK2
- ROCK1
- CLK1
- CLK4
- RET
- PRKAA1
- LATS1
- PRKACA
- PRKG1
- PRKD3
- PRKD2
- PRKACB
- PRKAG1
- PRKCD
- PRKCB
- SYK
- PRKCA
- MAP3K11
- MAP4K3
- LIMK1
- LIMK2
- MELK
- MARK4
- PEBP1
- MARK3
- PFKP
- MARK2
- MAPKAPK5
- PHKG2
- PIM1
- PIP4K2A
- PIP4K2C
- PKMYT1
- PKN2
- PDXK
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- TRUQAP
- Truqap
- AZD-5363
- AZC5363
- AZD5363
- CAPIVASERTIB (AZD5363)
- AZD 5363
- UNII-WFR23M21IE
- WFR23M21IE
- cc-638
- C21H25ClN6O2
- CHEMBL2325741
- Capivasertib?
- Capivasertib (JAN/USAN)
- CAPIVASERTIB [INN]
- CAPIVASERTIB [JAN]
- CAPIVASERTIB [USAN]
- Capivasertib (AZD5363)
- MLS006011179
- CAPIVASERTIB [WHO-DD]
- SCHEMBL390243
- GTPL7709
- DTXSID40150710
- EX-A285
- US10654855, Example 9
- BDBM443385
- MFCD22628785
- NSC764039
- NSC782347
- NSC799347
- s8019
- ZINC43204023
- AKOS027323693
- BCP9000365
- CCG-268989
- CS-1284
- DB12218
- NSC-764039
Look up CAPIVASERTIB in the interactive SynDRA portal →